Such therapies are in phase I of clinical studies in combination with immune checkpoint inhibitor antibodies [122], in the context of argininosuccinate synthase 1 (ASS1)—deficient cancers, normally melanoma, lymphoma, glioma or prostate cancers that rely on circulating arginine. The gene discussed is ASS1; the disease is cancer.